Goldman Sachs’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-218,481
| Closed | -$649K | – | 7279 |
|
|
2016
Q3 | $649K | Sell |
218,481
-63,935
| -23% | -$111K | ﹤0.01% | 4794 |
|
|
2016
Q2 | $421K | Sell |
282,416
-12,275
| -4% | -$28.1K | ﹤0.01% | 5016 |
|
|
2016
Q1 | $1.09M | Buy |
294,691
+195,186
| +196% | +$1.21M | ﹤0.01% | 4012 |
|
|
2015
Q4 | $1M | Sell |
99,505
-82,903
| -45% | -$998K | ﹤0.01% | 4289 |
|
|
2015
Q3 | $2.48M | Sell |
182,408
-49,532
| -21% | -$882K | ﹤0.01% | 3585 |
|
|
2015
Q2 | $4.4M | Sell |
231,940
-203,369
| -47% | -$4.4M | ﹤0.01% | 3075 |
|
|
2015
Q1 | $11.4M | Sell |
435,309
-452,311
| -51% | -$11.5M | ﹤0.01% | 2191 |
|
|
2014
Q4 | $18.6M | Buy |
887,620
+585,725
| +194% | +$14.8M | 0.01% | 1871 |
|
|
2014
Q3 | $10.1M | Buy |
301,895
+196,975
| +188% | +$6.11M | ﹤0.01% | 2363 |
|
|
2014
Q2 | $3.37M | Sell |
104,920
-77,109
| -42% | -$2.87M | ﹤0.01% | 3443 |
|
|
2014
Q1 | $8.41M | Buy |
182,029
+26,361
| +17% | +$1.55M | ﹤0.01% | 2521 |
|
|
2013
Q4 | $11M | Buy |
155,668
+147,977
| +1,924% | +$11.3M | ﹤0.01% | 2282 |
|
|
2013
Q3 | $660K | Sell |
7,691
-4,706
| -38% | -$399K | ﹤0.01% | 4932 |
|
|
2013
Q2 | $785K | Buy |
+12,397
| New | +$658K | ﹤0.01% | 4586 |
|
Goldman Sachs's AEGR Position: Q4 2016 in Review
Goldman Sachs sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 218,481 shares — an estimated $649K sold.
Goldman Sachs first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $18.6M in Q4 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Goldman Sachs reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Goldman Sachs sold 218,481 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $649K.
- Goldman Sachs first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Goldman Sachs's Aegerion Pharmaceuticals position peaked at $18.6M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.